ArticleFrontiers in pharmacology2025

Network meta-analysis and cost-effectiveness analysis comparing Cetuximab-β and Cetuximab for Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer.

Rongjun Tong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.